20.60NOK-0.48%Mkt Cap: 85.39M $P/E: 12.261d ago
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) in Africa, Europe, Asia, and North and South America. It offers metformin HCl; m…
Industry Peers
Drug Manufacturers - Specialty & Genericvs Drug Manufacturers - Specialty & Generic
P/E
Cheaper
P/B
Avg
Div Yield
Lower
1M Perf
Avg
Indicators:|
Key Statistics
Company
Market Cap85.39M $
Enterprise Value84.85M $
Revenue (TTM)42.02M $
Gross Profit21.68M $
Net Income (TTM)6.99M $
Revenue/Share0.9470 USD
Last Price20.60 NOK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees74
CountryNO
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)12.26
P/E (Forward)—
PEG—
EV/EBITDA8.17
EV/Revenue2.02
P/S2.03
P/B2.78
EPS (TTM)1.68
EPS (Forward)—
52W Range
19.4020% of range25.30
52W High25.30 NOK
52W Low19.40 NOK
Profitability
Gross Margin51.28%
Oper. Margin19.18%
EBITDA Margin24.71%
Profit Margin16.53%
ROE22.73%
ROA17.01%
Growth
Revenue Growth-2.50%
Earnings Growth-1.20%
Cash Flow & Leverage
Operating CF7.29M $
CapEx (TTM)1.56M $
FCF Margin3.68%
FCF Yield1.81%
Net Debt-544.70K $
Net Debt/EBITDA-0.05
Balance Sheet
Debt/Equity0.00
Current Ratio2.96
Quick Ratio1.83
Book Value/Sh7.415 NOK
Cash/Share0.1430 NOK
Dividends
Fwd Div Rate2.250 NOK
Trail. Div Rate1.500 NOK
Div. Yield10.92%
5Y Avg Yield—
Payout Ratio74.40%
Ex-Div DateMay 22, 2026
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.44.34M
Float21.97M
Insiders58.94%
Institutions13.74%
Technical
SMA 5021.52 (-4.3%)
SMA 20021.43 (-3.9%)
Beta0.62
S&P 52W Chg20.05%
Avg Vol (30d)32.70K
Avg Vol (10d)8.10K
Technical Indicators
RSI (14)44.8
MACD-0.2263
MACD Signal-0.3065
MACD Hist.+0.0802
BB Upper20.90 NOK
BB Middle20.57 NOK
BB Lower20.24 NOK
BB Width3.16%
ATR (14)0.3952 NOK
Vol Ratio (20d)0.04x